New CSF biomarkers on the block

A growing number of cerebrospinal fluid biomarkers are now available to capture different aspects of Alzheimer's disease. People are increasingly aware that these biomarkers represent a real‐time reflection of pathological mechanisms that are ongoing in the brain. These novel markers can be added to the panel of existing ones like amyloid beta, total Tau and phosphoTau that are currently used for sensitive diagnosis of Alzheimer's disease, either alone or in combination.